Ketorolac/phenylephrine - Omeros Corporation

Drug Profile

Ketorolac/phenylephrine - Omeros Corporation

Alternative Names: Omidria; OMS-302; OMS-302-PE; Phenylephrine and ketorolac injection 1%/0.3%; Phenylephrine/ketorolac

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Omeros Corporation
  • Class Analgesics; Anti-inflammatories; Antihypotensives; Decongestants; Ethanolamines; Eye disorder therapies; Indoles; Mydriatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Urologics
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Miosis; Postoperative pain

Most Recent Events

  • 05 Oct 2017 Omeros Corporation enters into a settlement agreement with Par Pharmaceutical, resolving Omeros’ patent litigation against Par’s filing of an ANDA seeking approval from the USFDA to market a generic version of ketorolac/phenylephrine .
  • 12 Sep 2017 Chemical structure information added
  • 08 Aug 2017 Omeros Corporation files sNDA for Posteoperative pain (In children, In infants, In neonates) and Miosis (In children, In infants, In neonates, Prevention) in USA before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top